Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bárczi (Budapest, Hungary), T. Nagy (Budapest, Hungary), K. Vincze (Budapest, Hungary), N. Eszes (Budapest, Hungary), A. Bohács (Budapest, Hungary), V. Müller (Budapest, Hungary). Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival. 1308

Member's Comments

No comment yet.

Related content which might interest you: Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Coexistence of chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer and impact on survival Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Does the lung function affect the survival time in patients with resected non-small cell lung cancer? Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery Year: 2007 Prevalence and characterization of interstitial lung disease in a lung cancer screening program Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Immunology-based therapeutic strategies in lung cancer and mesothelioma Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology Year: 2014 The burden of emphysema on lung cancer prognosis Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer Source: International Congress 2016 – Orphan diseases I Year: 2016 Common therapeutic approaches in IPF and lung cancer Source: Research Seminar 2015 Year: 2015 A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 The Asian experience in co-existing lung cancer and interstitial lung disease Source: International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance! Year: 2018 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Clinicopathologic features of patients with non-small cell lung cancer and chronic obstructive pulmonary disease undergoing lung cancer surgery Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Chronic obstructive pulmonary disease and interstitial lung disease could predict poor long-term survivals after pulmonary resection for lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 38s Year: 2002 A case series study on re-treatment to lung cancer after drug-induced interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Markers of angiogenesis in serum are correlating with disease progress in lung cancer Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Source: Eur Respir J, 50 (2) 1700050; 10.1183/13993003.00050-2017 Year: 2017 Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018 Year: 2018